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Abstract
A nine-year prospective study (2002–2010) on the prevalence of Candida dubliniensis among Candida bloodstream isolates
is presented. The germ tube positive isolates were provisionally identified as C. dubliniensis by presence of fringed and
rough colonies on sunflower seed agar. Subsequently, their identity was confirmed by Vitek2 Yeast identification system
and/or by amplification and sequencing of the ITS region of rDNA. In all, 368 isolates were identified as C. dubliniensis; 67.1%
came from respiratory specimens, 11.7% from oral swabs, 9.2% from urine, 3.8% from blood, 2.7% from vaginal swabs and
5.4% from other sources. All C. dubliniensis isolates tested by Etest were susceptible to voriconazole and amphotericin B.
Resistance to fluconazole ($8 mg/ml) was observed in 2.5% of C. dubliniensis isolates, 7 of which occurred between 2008–
2010. Of note was the diagnosis of C. dubliniensis candidemia in 14 patients, 11 of them occurring between 2008–2010.
None of the bloodstream isolate was resistant to fluconazole, while a solitary isolate showed increased MIC to 5-flucytosine
(.32 mg/ml) and belonged to genotype 4. A review of literature since 1999 revealed 28 additional cases of C. dubliniensis
candidemia, and 167 isolates identified from blood cultures since 1982. In conclusion, this study highlights a greater role of
C. dubliniensis in bloodstream infections than hitherto recognized.
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Introduction
Candida dubliniensis was first described in 1995 from oral
cavities of human immunodeficiency virus (HIV)-infected individ-
uals [1]. The species forms only a minor component of normal
microbiota but has a worldwide distribution [2]. Despite its close
relationship with C. albicans, which is the predominant pathogenic
species, the etiopathologic role of C. dubliniensis has mostly been
restricted to oral candidiasis. In recent years, however, C.
dubliniensis has increasingly been reported from patients with
candidemia [3–11]. Although the species is significantly less
virulent and genetically more clonal than C. albicans [12–14], the
reasons for its expanding role in invasive disease remain largely
unknown. Here, we report the prevalence of C. dubliniensis in
various clinical specimens over a nine-year period and discuss its
role in nosocomial candidemia.
Materials and Methods
C. dubliniensis isolates and their identification
The study was carried out at Mycology Reference Laboratory
(MRL) (Department of Microbiology, Faculty of Medicine,
Kuwait University) and included all Candida spp. isolates obtained
between 2002–2010. Candida spp. isolates either received from 15
different hospitals within Kuwait for identification and antifungal
susceptibility testing or recovered from various clinical specimens
at MRL were prospectively tested for germ tube formation. All
germ tube positive isolates were streaked on sunflower seed agar
[15] and incubated for 48 h at 30uC for formation of fringed and
rough colonies and chlamydospore production. Subsequently,
their identity was also confirmed by Vitek2 Yeast identification
system and/or by amplification and sequencing of the ITS region
of rDNA [16,17]. The study was approved by the Ethical
Committee of Health Sciences Center and Ministry of Health.
Molecular identification, genotype determination and
detection of 5-flucytosine resistance
The genotypes of C. dubliniensis isolates based on internal
transcribed spacer (ITS) region of rDNA were determined by PCR
amplification with genotype-specific primers and DNA sequencing
as described previously [18,19]. PCR products (10 ml) were
resolved by electrophoresis in 2% (wt/vol) agarose gels and
presence of a single amplicon of expected size indicated the
specific genotype. The results were extended by direct DNA
sequencing of the ITS region (containing ITS-1, 5.8S rRNA and
ITS-2) of rDNA. The amplicons obtained with ITS1 and ITS4
panfungal primers were purified and both strands were sequenced
using BigDye terminator v3.1 cycle sequencing kit and ABI 3130xl
GeneticAnalyzer (Applied Biosystems Inc.). The ITS1FS, ITS2,
ITS3 and ITS4RS were used as sequencing primers [19,20].
Specific genotypes were assigned based on maximum identity in
BLAST searches [21]. The detection of 5-flucytosine resistance-
conferring mutations in CdFCA1 gene codon 29 was carried out by
PCR amplification using FCA1F and FCA1R primers, the
amplicons were purified and subjected to restriction digestion
with Mbo I to generate RFLP patterns or sequenced as described
previously [18,22]. Pair-wise comparisons with sequences of 5-FC-
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formed using ClustalW.
Susceptibility testing by E-test
Antifungal susceptibility by E-test was performed on RPMI
1640 agar medium supplemented with 2% glucose with pH
adjusted to 7.0 with 0.165 M MOPS buffer as described
previously [17]. Etest strips for fluconazole, amphotericin B, and
5- fluorocytosine were obtained from AB BIODISK (Solna,
Sweden). The test was performed according to manufacturer’s
instructions. Briefly, 140 mm diameter petri plates were poured
with 60 ml RPMI medium containing 1.5% agar and allowed to
solidify. The agar surface was uniformly inoculated by nontoxic
cotton swab dipped in yeast cell suspension of the test isolates after
adjusting their turbidity to 0.5 McFarland standard. The plates for
minimum inhibitory concentration (MIC) were read after 24 h of
incubation at 35uC. The MICs were determined at the lowest drug
concentrations at which the border of the elliptical inhibition zone
intersected the strip scale. Reference strains of C. krusei (ATCC
6258), C. parapsilosis (ATCC22019) and C. albicans (ATCC90028)
were used for quality control. The resistance to fluconazole
($8 mg/ml) was determined by applying revised CLSI/EUCAST
breakpoints [21].
Statistical analysis
Mann-Whitney test was applied to determine significance of
differences observed in mean MIC values of fluconazole during
the three sub-periods of the study (2002 to 2004, 2005 to 2007,
and 2008 to 2010). SPSS version 17.0 was used for statistical
analysis and a P value of ,0.05 was considered as significant.
Results
During the 9-year study period (2002–2010), 368 isolates of C.
dubliniensis were prospectively identified. These included 54
(14.7%) isolates during 2002–2004, 150 (40.7) isolates during
2005–2007, and 164 (44.6%) isolates during 2008–2010. Of these,
247 (67.1%) came from respiratory (sputum and endotracheal
secretions) specimens, 43 (11.7%) from oral swabs, 34 (9.2%) from
urine, 14 (3.8%) from blood, 10 (2.7%) from vaginal swabs and 20
(5.4%) from other specimens. Of the 121 isolates (including all
bloodstream isolates) genotyped, 82 belonged to genotype 1 and
38 isolates belonged to genotype 4. The remaining isolates
belonged to genotypes 5–9 [18]. All 38 isolates belonging to
genotype 4 were resistant to 5-flucytosine and contained S29L
mutation at codon 29 of CdFCA1 gene [18,22]. Of note was the
enhanced frequency of isolation of C. dubliniensis from 14 blood
specimens obtained from 14 patients. Of the total of 1154 Candida
spp. blood culture isolates received, the distribution of C.
dubliniensis during the three sub-periods of the study was as
follows: one of 244 (0.4%) between 2002–2004, two of 356 (0.6%)
between 2005–2007, and 11 of 554 (2%) between 2008–2010
(Table 1). All C. dubliniensis candidemia patients were diagnosed at
different time points during the indicated periods.
The particulars of 11 patients yielding C. dubliniensis in blood
cultures whose records were available for review are presented in
Table 2. All patients were immunocompromised and had one or
more risk factors. Three of them occurred in males. Their age
ranged from 4–85 years. Four of the patients were treated with
fluconazole, two each with voriconazole and amphotericin B (lipid
formulation) and one with caspofungin. All blood culture isolates
were susceptible to fluconazole, amphotericin B and caspofungin.
A solitary blood culture isolate was resistant to 5-flucytosine and
belonged to genotype 4. Four of the patients (Cases 1, 7, 10 and
11) died, two of them before the blood cultures became positive,
hence no antifungal therapy was administered. C. dubliniensis was
the only pathogen isolated from blood culture of two of these four
patients.
The data on MIC50, MIC90, MIC range and geometric mean
of MICs of C. dubliniensis isolates are presented in Table 3. All C.
dubliniensis isolates that were available for testing were susceptible
to amphotericin B and voriconazole. Eight (2.5%) isolates were
resistant to fluconazole with MICs ranging between $8 mg/ml to
32 mg/ml [23]. There was marginal increase in geometric mean of
MIC values of fluconazole during the three sub-periods of the
study: 2002–2004 (n=54), 0.224 mg/ml; 2005–2007 (n=131),
0.307 mg/ml; and 2008–2010 (n=135), 0.338 mg/ml. These
differences in mean MICs were not significant (p=0.219). As
many as 60 isolates (10 of 54 during 2002–2004, 29 out of 109 in
2005–2007 and 21 out of 86 in 2008–2010) were resistant to 5-
flucytosine and all 38 that were sequenced belonged to genotype 4
[18].
Discussion
The true prevalence of C. dubliniensis fungemia largely remains
unknown because of the difficulty in readily distinguishing this
species from the morphologically similar species, C. albicans. This
study is noteworthy as it prospectively identified all germ tube
positive Candida bloodstream isolates for the presence of C.
dubliniensis. We observed that prevalence of C. dubliniensis among
bloodstream isolates increased from 0.4% between 2002–2004 to
2% between 2008–2010 (Table 1). The reasons for increased
occurrence of candidemia cases due to C. dubliniensis are unclear.
Bloodstream C. dubliniensis isolates formed 3.8% (14 of 368) of the
total isolates of this species recovered from all clinical specimens.
In a previous study from Saudi Arabia, the overall prevalence of C.
dubliniensis was 3.3% among 823 yeast isolates recovered from
different clinical specimens [24]. Two (16.7%) of their blood-
stream isolates were re-identified as C. dubliniensis. Several
retrospective and prospective studies published during 2002–
2011 have reported on the prevalence of C. dubliniensis among
bloodstream Candida spp. isolates (Table S1) [6,10,24–42].
Generally, the prevalence of C. dubliniensis varied between 0.5%
to 7.0% with the exception of two studies involving small number
of isolates [24,31], where it was 16.7% and 10.0%, respectively. In
these two studies, only germ tube positive bloodstream isolates
were included. In a recent fungemia surveillance study from
Denmark, Arendrup et al. [41] reported a prevalence of 1.2% to
3.1% over a six-year period and 74 (2.6%) of C. dubliniensis isolates
came from blood cultures.
Since the first description of C. dubliniensis from oral cavities of
HIV-positive patients from Ireland [1,43], subsequent epidemio-
logical studies have revealed that this species is prevalent globally
Table 1. Occurrence of C. dubliniensis among bloodstream
isolates of Candida spp.
Year
Total bloodstream
Candida spp. isolates
No. (%) of
C. dubliniensis isolates
2002–2004 244 1 (0.4)
2005–2007 356 2 (0.6)
2008–2010 554 11 (2.0)
Total 1154 14 (1.2)
doi:10.1371/journal.pone.0032952.t001
C. dubliniensis as a Bloodstream Pathogen
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possibility of inter-host transmission [44,45]. The species has now
been reported from other body sites/specimens, such as vagina,
urine, skin, and feces/gastrointestinal tract of both HIV-positive
and HIV-negative patients [2,16,17,46,47]. There are now
increasing reports that C. dubliniensis has the potential to cause
invasive disease in different groups of immunocompromised
patients [2], possibly originating from host’s own flora. Although
C. dubliniensis is closely related to C. albicans, it is responsible for far
fewer infections in humans. It is rare that patients colonized with
this species develop candidemia [2]. The reasons for this limited
ability of C. dubliniensis to cause invasive disease has been the focus
of recent studies [48–50]. It has been shown that C. dubliniensis
genome lacks important hypha-related virulence genes (e.g., ALS3
and HYR1) and it also has limited ability to undergo yeast-to-
hyphal transformation [49,50], which in turn may affect its
potential to invade deeper tissue.
A review of literature since 1999 revealed 32 cases of
bloodstream infection due to C. dubliniensis [3,4,6–9,25,42,51–
59]. They originated from different geographic regions (Europe-8,
North America-17, Argentina-4, Australia-2, Singapore-1). All of
them had underlying conditions or risk factors including six with
HIV infection. Their ages ranged between 1–68 years. Of 28
patients for whom detailed particulars were available (Table S2),
15 were males. Six of these cases occurred in pediatric age group
and 14 of 28 (50%) patients died. In three of them, no antifungal
agent was administered. One patient died due to rhabdomyosar-
coma despite receiving treatment with fluconazole. It is notewor-
thy that first of the three cases of C. dubliniensis fungemia were
reported from Europe in non-HIV-infected patients with bone
marrow transplantation and chemotherapy-induced neutropenia
[8]. This was followed by a report of four additional cases from the
United States including one who was infected with HIV [3]. This
was believed to be the first case of C. dubliniensis candidemia in
HIV-infected patient. Subsequently, 21 additional cases of C.
dubliniensis fungemia were reported from many other countries
(Table S2). However, the isolation of nearly 200 strains of C.
dubliniensis from blood indicates that 28 described cases of
candidemia represent only a fraction of total candidemia cases
caused by this species. Furthermore, since blood culture positivity
from candidemia patients seldom exceeds 50%, C. dubliniensis may
be responsible for far greater number of candidemia cases than
hitherto recognized.
All our C. dubliniensis isolates were susceptible to voriconazole
and amphotericin B. However, 2.5% (8 out of 320) of the isolates
were considered resistant (MICs$8 mg/ml) according to harmo-
nized CLSI and EUCAST susceptibility breakpoints for Candida
spp., which do not include C. dubliniensis [23]. It is noteworthy that
none of the 11 C. dubliniensis bloodstream isolates was resistant to
fluconazole. Generally, C. dubliniensis isolates are known to be
susceptible to a wide range of antifungal agents [36]. Recently,
Arendrup et al. [41] reported occurrence of fluconazole resistance
in 3.1% (2 of 65) of C. dubliniensis bloodstream isolates using
EUCAST breakpoint (MIC.4 mg/ml). It is unclear if marginal
increase in fluconazole MICs (as indicated by geometric mean,
Table 3) in the present study have in any manner contributed to
increased occurrence of C. dubliniensis candidemia during 2008–
2010. In this context, a reference may be made to a recent
publication by Oxman et al. [60], who found that a significant
number of candidemia episodes were caused by isolates that
showed reduced susceptibility to fluconazole while still considered
to be fully susceptible. Although none of our candidemia patient
was on fluconazole prophylaxis, it has been shown that exposure to
fluconazole may enhance adherence of C. dubliniensis to oral
epithelium [61] and may also facilitate replacement of C. albicans
with C. dubliniensis [62]. The impact of fluconazole therapy/
prophylaxis on the epidemiology C. dubliniensis candidemia is not
known. Some investigators believe that widespread exposure to
azoles may have contributed to increasing incidence of less
susceptible non-albicans Candida spp. as bloodstream pathogens
[63], a view that has not been shared by others [64].
In conclusion, a 9-year prospective study on the prevalence of C.
dubliniensis among bloodstream Candida spp. isolates with an overall
prevalence of 1.2%, is presented. Of 14 cases of C. dubliniensis
candidemia, 11 were diagnosed between 2008–2010, thus
highlighting an increasing role of C. dubliniensis in bloodstream
infections in Kuwait in recent years. These observations are
consistent with the global trend pointing towards changing
epidemiology of candidemia in favor of non-albicans Candida spp.
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Table 3. Antifungal susceptibility profile of Candida
dubliniensis isolates.
Duration/Antifungals (n
a) MIC 50 MIC 90 Range GM
2002–2004
Amphotericin B 54 0.023 0.094 0.002–0.5 0.023
Fluconazole 54 0.25 0.75 0.047–1 0.244
Flucytosine* 54 0.012 $32 0.003- $32 0.045
Voriconazole 54 0.006 0.016 0.002–0.023 0.007
2005–2007
Amphotericin B 126 0.012 0.064 0.002–0.75 0.013
Fluconazole 131 0.25 1 0.047–8 (1) 0.307
Flucytosine* 109 0.023 $32 0.004- $32 0.134
Voriconazole 108 0.012 0.047 0.004- 0.25 0.014
2008–2010
Amphotericin B 138 0.012 0.064 0.002–0.75 0.014
Fluconazole 135 0.25 4 0.125–32 (7) 0.338
Flucytosine* 86 0.032 $32 0.004- $32 0.146
Voriconazole 133 0.016 0.125 0.004-0.25 0.020
*Geometric mean for flucytosine resistant isolates was calculated at 32 mg/ml.
The numbers of the resistant isolates for the three periods were 10, 29, and 21,
respectively. Numbers in parentheses indicate isolates with MIC $8 mg/ml [23].
aNumber of isolates tested.
doi:10.1371/journal.pone.0032952.t003
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